Orna Therapeutics, Inc.
Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Their technology focuses on engineered circular RNA and lipid nanoparticle delivery systems, aiming to transform patient care across oncology, autoimmune, infectious, and genetic diseases. The company emphasizes innovation, collaboration, and a commitment to advancing RNA therapeutics to improve lives.
Industries
Nr. of Employees
medium (51-250)
Orna Therapeutics, Inc.
Patents
Apparatus and method for training a tunable data structure to predict internal ribosome entry site (IRES) activity
US-12175354-B1
View Details
Apparatus and method for training a tunable data structure to predict internal ribosome entry site (IRES) activity
US-12175354-B1
View DetailsProducts
Circular RNA therapeutic platform with LNP delivery
An integrated platform pairing engineered circular RNA constructs with lipid nanoparticle delivery systems to enable vaccines, in vivo CAR therapies, and RNA editing approaches targeting extra-hepatic tissues.
In vivo panCAR therapeutic programs (CD19 and BCMA targets)
Program-level assets intended to induce CAR expression in vivo to deplete target B cells (CD19) for autoimmune disease and to target BCMA for multiple myeloma; programs are being advanced toward clinical studies.
Circular RNA therapeutic platform with LNP delivery
An integrated platform pairing engineered circular RNA constructs with lipid nanoparticle delivery systems to enable vaccines, in vivo CAR therapies, and RNA editing approaches targeting extra-hepatic tissues.
In vivo panCAR therapeutic programs (CD19 and BCMA targets)
Program-level assets intended to induce CAR expression in vivo to deplete target B cells (CD19) for autoimmune disease and to target BCMA for multiple myeloma; programs are being advanced toward clinical studies.
Services
Strategic collaborations with pharmaceutical companies for co-development of vaccines, infectious disease therapeutics, oncology and genetic disease programs.
Design and execution of preclinical studies including biodistribution, pharmacodynamic assessments, and efficacy models in humanized mice and non-human primates to support clinical translation.
Strategic collaborations with pharmaceutical companies for co-development of vaccines, infectious disease therapeutics, oncology and genetic disease programs.
Design and execution of preclinical studies including biodistribution, pharmacodynamic assessments, and efficacy models in humanized mice and non-human primates to support clinical translation.
Expertise Areas
- Circular RNA therapeutics
- LNP delivery and formulation
- In vivo cell engineering (in vivo CAR platforms)
- Preclinical pharmacology and animal models (humanized mice, NHPs)
Key Technologies
- Circular RNA constructs
- Lipid nanoparticle (LNP) formulation
- In vivo CAR expression platforms
- RNA editing platforms
News & Updates
Orna Therapeutics announced the presentation of new preclinical data supporting its in vivo CAR therapy approach in autoimmune diseases during the ASGCT Annual Meeting in May 2025. The data demonstrated successful delivery of their panCAR LNP to immune cell types and robust B cell depletion in non-human primates, highlighting the potential of their in vivo CAR T therapy.
Orna Therapeutics announced an upcoming presentation at the ASGCT Annual Meeting in May 2025, highlighting data supporting its in vivo CAR therapy approach in autoimmune diseases, including deep and sustained B cell depletion in non-human primates.
Leadership in RNA Therapeutics and Autoimmune Disease Treatment
Orna's innovative approach with circular RNA and lipid nanoparticle delivery systems positions it as a leader in developing in vivo therapies for autoimmune and oncology indications.
Advancement of in vivo CAR T therapy
Successful preclinical data demonstrating the potential of in vivo CAR T therapy using circular RNA technology, with plans to advance into clinical trials in 2026.
Orna Therapeutics announced the presentation of new preclinical data supporting its in vivo CAR therapy approach in autoimmune diseases during the ASGCT Annual Meeting in May 2025. The data demonstrated successful delivery of their panCAR LNP to immune cell types and robust B cell depletion in non-human primates, highlighting the potential of their in vivo CAR T therapy.
Orna Therapeutics announced an upcoming presentation at the ASGCT Annual Meeting in May 2025, highlighting data supporting its in vivo CAR therapy approach in autoimmune diseases, including deep and sustained B cell depletion in non-human primates.
Leadership in RNA Therapeutics and Autoimmune Disease Treatment
Orna's innovative approach with circular RNA and lipid nanoparticle delivery systems positions it as a leader in developing in vivo therapies for autoimmune and oncology indications.
Advancement of in vivo CAR T therapy
Successful preclinical data demonstrating the potential of in vivo CAR T therapy using circular RNA technology, with plans to advance into clinical trials in 2026.